Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma

Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Dufour, 2000, Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring, Clin Chem, 46, 2050, 10.1093/clinchem/46.12.2050 Koteish, 2002, Screening for hepatocellular carcinoma, J Vasc Interv Radiol, 13, 185, 10.1016/S1051-0443(07)61785-0 Ryder, 2003, Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults, Gut, 52, 1, 10.1136/gut.52.suppl_3.iii1 Lamerz R, Hayes P, Hoffmann RT, Löhe F, Shiratori Y, Taketa K. National Academy of clinical biochemistry guidelines for the use of tumor markers in primary liver cancer 2003, http://www.nacb.org/lmpg/tumor/chp3d_liver.pdf. Tsukuma, 1993, Risk factors for hepatocellular carcinoma among patients with chronic liver disease, N Engl J Med, 328, 1797, 10.1056/NEJM199306243282501 Cheng, 2007, AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein, J Chin Med Assoc, 70, 310, 10.1016/S1726-4901(08)70011-X Nakagawa, 2008, Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients, J Proteome Res, 7, 2222, 10.1021/pr700841q Wang, 2005, Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma, World J Gastroenterol, 11, 6115, 10.3748/wjg.v11.i39.6115 Tommaso, 2009, The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma, J Hepatol, 50, 746, 10.1016/j.jhep.2008.11.014 Sauerland, 2009, Cancers of the pancreas and hepatobiliary system, Semin Oncol Nurs, 25, 76, 10.1016/j.soncn.2008.10.006 Pissaia, 2009, Significance of serum tumor markers carcinoembryonic antigen, CA19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation, Transplant Proc, 41, 682, 10.1016/j.transproceed.2008.12.015 Khalifa, 1999, Differential tumor markers and hepatitis markers profile in liver tumors, Anticancer Res, 19, 2495 Usui, 1992, Hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9, Intern Med, 31, 791, 10.2169/internalmedicine.31.791 Filmus, 2001, Glypicans: proteoglycans with a surprise, J Clin Invest, 108, 497, 10.1172/JCI200113712 Tetsuya, 2004, Identification of glypican-3 as a novel tumor marker for melanoma, Clin Cancer Res, 10, 6612, 10.1158/1078-0432.CCR-04-0348 Wang B, Wab M. Methods for diagnosing and treating prostate cancer, US Patent 20070154964. Sung, 2003, Glypican-3 is overexpressed in human hepatocellular carcinoma, Cancer Sci, 94, 259, 10.1111/j.1349-7006.2003.tb01430.x Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9 Tetsuya, 2003, Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker, Biochem Biophys Res Commun, 306, 16, 10.1016/S0006-291X(03)00908-2 Zhu, 2001, Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders, Gut, 48, 558, 10.1136/gut.48.4.558 Yamauchi, 2005, The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma, Mod Pathol, 18, 1591, 10.1038/modpathol.3800436 Murthy, 2000, Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma, Oncogene, 19, 410, 10.1038/sj.onc.1203322 Xiang, 2001, Glypican-3 expression is silenced in human breast cancer, Oncogene, 20, 7408, 10.1038/sj.onc.1204925 Kim, 2003, The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor, Am J Respir Cell Mol Biol, 29, 694, 10.1165/rcmb.2003-0061OC Zhu, 2002, Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer, Am J Surg, 184, 78, 10.1016/S0002-9610(02)00884-X Lin, 1999, Frequent silencing of the GPC3 gene in ovarian cancer cell lines, Cancer Res, 59, 807 Pilia, 1996, Mutations in GPC3, a glypican gene, cause the Simpson–Golabi–Behmel overgrowth syndrome, Nature Genetics, 12, 241, 10.1038/ng0396-241 Hippo, 2004, Identification of soluble NH2-terminal fragment of glypican-3 as a serum marker for early-stage of hepatocellular carcinoma, Cancer Res, 64, 2418, 10.1158/0008-5472.CAN-03-2191 Capurro, 2005, Glypican-3 as a serum marker for hepatocellular carcinoma, Cancer Res, 65, 372, 10.1158/0008-5472.372.65.1 Emoto, 2005, Mechanisms of heat-induced antigen retrieval: does pH or ionic strength of the solution play a role for refolding antigens, J Histochem Cytochem, 53, 1311, 10.1369/jhc.5C6627.2005 Hara, 1994, Noncompetitive immunoassay of thyroxine using a liquid-phase binding assay, Anal Chem, 66, 351, 10.1021/ac00075a007 Tommaso, 2007, Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, 45, 725, 10.1002/hep.21531